These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26384512)

  • 21. Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice.
    Atri A
    Handb Clin Neurol; 2016; 136():971-84. PubMed ID: 27430453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.
    Rabinovici GD; Karlawish J; Knopman D; Snyder HM; Sperling R; Carrillo MC
    Alzheimers Dement; 2016 Apr; 12(4):510-5. PubMed ID: 27103054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
    Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
    Villemagne VL; Rowe CC
    J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Awareness disorders in Alzheimer's disease and in mild cognitive impairment].
    Jacus JP; Dupont MP; Herades Y; Pelix C; Large H; Baud M
    Encephale; 2014 Apr; 40(2):180-7. PubMed ID: 24630532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's disease.
    Scheltens P; Blennow K; Breteler MM; de Strooper B; Frisoni GB; Salloway S; Van der Flier WM
    Lancet; 2016 Jul; 388(10043):505-17. PubMed ID: 26921134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear medicine imaging in dementia: a practical overview for hospitalists.
    Toney LK; McCue TJ; Minoshima S; Lewis DH
    Hosp Pract (1995); 2011 Aug; 39(3):149-60. PubMed ID: 21881402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammation and anti-inflammatory strategies for Alzheimer's disease--a mini-review.
    McNaull BB; Todd S; McGuinness B; Passmore AP
    Gerontology; 2010; 56(1):3-14. PubMed ID: 19752507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging discrepancies between magnetic resonance imaging and brain perfusion single-photon emission computed tomography in the diagnosis of Alzheimer's disease, and verification with amyloid positron emission tomography.
    Yokoyama S; Kajiya Y; Yoshinaga T; Tani A; Hirano H
    Psychogeriatrics; 2014 Jun; 14(2):110-7. PubMed ID: 24954834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease.
    Minter MR; Taylor JM; Crack PJ
    J Neurochem; 2016 Feb; 136(3):457-74. PubMed ID: 26509334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The emerging role of PET imaging in dementia.
    Iaccarino L; Sala A; Caminiti SP; Perani D
    F1000Res; 2017; 6():1830. PubMed ID: 29071066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroimaging as a diagnostic tool in dementia with Lewy bodies.
    Small GW
    Dement Geriatr Cogn Disord; 2004; 17 Suppl 1():25-31. PubMed ID: 14676466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
    Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
    Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
    Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
    Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
    Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
    Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What can imaging tell us about cognitive impairment and dementia?
    Narayanan L; Murray AD
    World J Radiol; 2016 Mar; 8(3):240-54. PubMed ID: 27029053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy for Alzheimer's disease and related dementias.
    Bednar MM
    Prog Mol Biol Transl Sci; 2019; 168():289-296. PubMed ID: 31699322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroinflammation: A Potential Risk for Dementia.
    Ahmad MA; Kareem O; Khushtar M; Akbar M; Haque MR; Iqubal A; Haider MF; Pottoo FH; Abdulla FS; Al-Haidar MB; Alhajri N
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.